As highlighted in our latest ICARE newsletter, a new study in BRCA1/2 carriers with advanced breast cancer found:
- PARP inhibitors showed some activity even in patients with platinum resistant/unresponsive disease.
- However, the optimal delivery of platinum agents and PARP inhibitors was not clear.
Read the full article to learn more at: https://pubmed.ncbi.nlm.nih.gov/37437366/
Reference: Valenza, et al. Eur J Cancer. 2023;190:112944. PMID: 37437366.
We also encourage you to read the full ICARE newsletter for other clinical and research updates at https://inheritedcancer.net/newsletters/